Hawkins Inc.

10/26/2026 | Press release | Distributed by Public on 10/26/2026 14:15

Quarterly Report for Quarter Ending September 27, 2026 (Form 10-Q)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following is a discussion and analysis of our financial condition and results of operations for the three and six months ended September 27, 2026 as compared to the three and six months ended September 28, 2025. This discussion should be read in conjunction with the condensed consolidated financial statements and notes to condensed consolidated financial statements included in this quarterly report on Form 10-Q and Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended March 29, 2026.
Overview
We derive substantially all of our revenues from the sale of water treatment, specialty ingredients, and chemistry products, and equipment to our customers in a wide variety of industries. We believe that we create value for our customers through superb service and support, quality products, personalized applications and trustworthy and creative employees.
Business Acquisitions
We completed the following acquisitions in the first half of fiscal 2027 and fiscal 2026. The results of operations since the date of each acquisition and the assets, including goodwill associated with these acquisitions, are included in our Water Treatment segment with the exception of the MakWood lactate business, which is included in our Food & Health Sciences segment. Certain acquisitions discussed below are not included in Note 2 to our Condensed Consolidated Financial Statements as they were not deemed to be material enough to warrant disclosure.
Fiscal 2027
•On September 1, 2026, we acquired substantially all the assets and assumed certain liabilities of Dave Symonds & Associates, Inc. ("Symonds") for approximately $1.6 million. Symonds distributes water treatment products, primarily blended phosphates for corrosion control and sequestration, to water treatment customers in Florida.
•On April 30, 2026, we acquired substantially all the assets and assumed certain liabilities of Aqua-Chem, Inc. ("Aqua-Chem") for approximately $3.6 million. Aqua-Chem provides water treatment products to commercial pools, including chemistry, equipment, and service, mainly to Nebraska and Iowa customers.
Fiscal 2026
•On December 3, 2025, we acquired substantially all the assets and assumed certain liabilities of Redbird Chemical, Inc. ("Redbird") for $4.6 million. Redbird distributed chemicals to its customers in eastern Texas within both the water treatment and industrial markets.
•On August 29, 2025, we acquired substantially all the assets and assumed certain liabilities of StillWaters Technology, Inc. ("StillWaters") for $4.3 million. StillWaters distributed water treatment chemicals and equipment for its customers in Alabama.
•On July 2, 2025, we acquired the lactate business of MakWood, Inc. for $1.9 million. We had previously been party to a Distribution Agreement with MakWood for certain lactate products under the Mak Lak trade name. This acquisition agreement terminated the Distribution Agreement, and resulted in our acquisition of the lactate distribution business, including the customer list and associated brand name.
•On July 1, 2025, we acquired substantially all the assets and assumed certain liabilities of PhillTech, LLC ("PhillTech") for $5.0 million. Located in Courtland, AL, PhillTech manufactured and distributed coagulants and corrosion control products for its water treatment customers.
•On June 13, 2025, we acquired substantially all the assets and assumed certain liabilities of Hendrickson Enterprises, LLC and Polymer Technologies, LLC (collectively, "Hendrickson") for approximately $1.5 million. Hendrickson distributed water treatment chemicals and equipment to its customers via direct shipments from suppliers.
•On April 25, 2025, we acquired substantially all of the assets and assumed certain liabilities of WaterSurplus and related entities for approximately $149.9 million paid at closing, with an additional amount payable as an earnout of up to $53.7 million based on cumulative gross profit for the first five years. WaterSurplus is located in Rockford, IL and delivers sustainable water treatment solutions to customers throughout the United States.
The aggregate annual revenue of the eight businesses acquired during fiscal 2026 and the first half of fiscal 2027 totaled approximately $53.6 million, as determined using the applicable twelve-month period preceding each respective acquisition date.
Subsequent to the end of the second quarter of fiscal 2027, on September 29, 2026, we acquired substantially all of the assets of Eagle Labs, Inc. ("Eagle Labs") for approximately $14.0 million. Eagle Labs distributes water treatment products directly to customers in Texas from its operations in the Dallas-Fort Worth region and has in-house manufacturing capabilities.
Financial Results
We focus on total operating income when evaluating our financial results as opposed to profitability as a percentage of sales, as sales dollars tend to fluctuate as raw material prices rise and fall, particularly in our Water Treatment and Industrial Solutions segments. The costs for certain of our raw materials can rise or fall rapidly, causing fluctuations in gross profit as a percentage of sales.
We use the last in, first out ("LIFO") method of valuing the majority of our inventory, which causes the most recent product costs to be recognized in our income statement. The LIFO inventory valuation method and the resulting cost of sales are consistent with our business practices of pricing to current chemical raw material prices.
We disclose the sales of our bulk commodity products as a percentage of total sales dollars for our Water Treatment and Industrial Solutions segments. Our definition of bulk commodity products includes products that we do not modify in any way, but receive, store, and ship from our facilities, or direct ship to our customers in large quantities. We disclose the percentage of our overall sales that consist of sales of bulk commodity products as these products are generally distributed and we do not add significant value to these products in comparison to our non-bulk products. Sales of these products are generally highly competitive and price sensitive. As a result, bulk commodity products generally have our lowest margins.
Results of Operations
The following table sets forth the percentage relationship of certain items to sales for the period indicated:
Three months ended Six months ended
September 27, 2026 September 28, 2025 September 27, 2026 September 28, 2025
Sales 100.0 % 100.0 % 100.0 % 100.0 %
Cost of sales (75.6) % (75.9) % (76.1) % (75.6) %
Gross profit 24.4 % 24.1 % 23.9 % 24.4 %
Selling, general and administrative expenses (11.1) % (12.0) % (11.1) % (11.3) %
Operating income 13.3 % 12.1 % 12.8 % 13.1 %
Interest expense, net (0.8) % (1.4) % (0.9) % (1.2) %
Other income 0.1 % 0.3 % 0.3 % 0.3 %
Income before income taxes 12.6 % 11.0 % 12.2 % 12.2 %
Income tax expense (3.7) % (2.9) % (3.3) % (3.1) %
Net income 8.9 % 8.1 % 8.9 % 9.1 %
Three Months Ended September 27, 2026 Compared to Three Months Ended September 28, 2025
Sales
Sales were $313.8 million for the three months ended September 27, 2026, an increase of $33.4 million, or 12%, from sales of $280.4 million in the same period a year ago. All of our segments grew by 5% or more as compared to the prior year. Sales increased as a result of 11% organic sales growth and approximately $3.7 million of sales from acquired businesses.
Water Treatment Segment. Water Treatment segment sales increased $24.1 million, or 16%, to $175.0 million for the three months ended September 27, 2026, from sales of $150.9 million in the same period a year ago. Sales of bulk commodity products in the Water Treatment segment were approximately 11% of sales dollars in the current quarter and 8% in the same period a year ago. Organic sales grew 14%, driven primarily by increased volumes, along with improved pricing on certain of our products. Acquired businesses contributed approximately $3.7 million in additional sales.
Food & Health Sciences Segment. Food & Health Sciences segment sales increased $3.8 million, or 5%, to $76.7 million for the three months ended September 27, 2026, from sales of $72.9 million in the same period a year ago. Sales dollars increased as a result of increased volumes of our nutrition, food ingredients, and pharmaceutical products, partially offset by decreased sales of our agricultural products.
Industrial Solutions Segment. Industrial Solutions segment sales increased $5.6 million, or 10%, to $62.2 million for the three months ended September 27, 2026, from sales of $56.6 million in the same period a year ago. Sales of bulk commodity products in the Industrial Solutions segment were approximately 22% of sales dollars in the current quarter and 21% in the same period a year ago. Sales increased as a result of increased pricing and favorable product mix, which more than offset lower sales volumes.
Gross Profit
Gross profit increased $9.0 million, or 13%, to $76.6 million, or 24% of sales, for the three months ended September 27, 2026, from $67.6 million, or 24% of sales, in the same period a year ago. During the current quarter, the LIFO reserve increased, and gross profit decreased, by $1.9 million primarily due to higher raw material costs. In the same period a year ago, the LIFO
reserve increased, and gross profit decreased, by $0.3 million. The $1.6 million year-over-year impact of the unfavorable LIFO reserve was partially offset by $1.3 million of refunds of previously paid tariffs, which were recorded as a reduction of cost of sales. The refunded tariffs related to products for which customer pricing had not been increased in response to tariffs.
Water Treatment Segment. Gross profit for the Water Treatment segment increased $8.4 million, or 20%, to $51.7 million, or 30% of sales, for the three months ended September 27, 2026, from $43.3 million, or 29% of sales, in the same period a year ago. During the current quarter, the LIFO reserve increased, and gross profit decreased, by $0.5 million. In the same period a year ago, the LIFO reserve decreased, and gross profit increased minimally. The $0.5 million year-over-year impact of the unfavorable LIFO reserve increase was more than offset by $1.2 million of refunds of previously paid tariffs, which were recorded as a reduction of cost of sales. The increase in gross profit was primarily driven by higher sales.
Food & Health Sciences Segment. Gross profit for the Food & Health Sciences segment decreased $0.6 million, or 4%, to $14.9 million, or 19% of sales for the three months ended September 27, 2026, from $15.5 million, or 21% of sales, in the same period a year ago. During the current quarter, the LIFO reserve increased, and gross profit decreased, by $0.7 million. In the same period a year ago, the LIFO reserve increased, and gross profit decreased, by $0.2 million. Gross profit decreased as lower margins in our food and pharmaceutical products and the $0.5 million year-over-year impact of the unfavorable LIFO reserve more than offset the benefit of higher sales and improved margins in our nutrition and agriculture products.
Industrial Solutions Segment. Gross profit for the Industrial Solutions segment increased $1.1 million, or 12%, to $10.0 million, or 16% of sales for the three months ended September 27, 2026, from $8.9 million, or 16% of sales, in the same period a year ago. During the current quarter, the LIFO reserve increased, and gross profit decreased, by $0.7 million. In the same period a year ago, the LIFO reserve increased, and gross profit decreased, by $0.1 million. The benefit of higher sales and favorable product mix was partially offset by the $0.6 million year-over-year impact of the unfavorable LIFO reserve increase.
Selling, General and Administrative Expenses
Selling, general and administrative ("SG&A") expenses increased $1.0 million, or 3%, to $34.7 million, or 11% of sales, for the three months ended September 27, 2026, from $33.7 million, or 12% of sales, in the same period a year ago. This included $0.4 million due to added costs from the acquired businesses in our Water Treatment segment. SG&A expenses also increased due to increases in other variable costs, including variable pay and other personnel costs. These increases were partially offset by a $0.5 million decrease in non-qualified deferred compensation plan expense, as appreciation in the market value of plan investments was lower than in the same period a year ago. Deferred compensation plan expense is offset by a corresponding gain on plan investments recorded in other income (expense).
Operating Income
Operating income increased $8.0 million, or 23%, to $41.9 million, or 13% of sales, for the three months ended September 27, 2026, from $33.9 million, or 12% of sales, in the same period a year ago due to the combined impact of the factors discussed above.
Interest Expense, Net
Interest expense decreased $1.2 million to $2.6 million for the three months ended September 27, 2026 compared to $3.8 million in the same period a year ago. Interest expense decreased as a result of $50.0 million in net debt repayments since the second quarter of fiscal 2026.
Other Income
Other income was $0.3 million for the three months ended September 27, 2026 compared to $0.7 million in the same period a year ago. The income represents gains recorded on investments held for our non-qualified deferred compensation plan. The amounts recorded as a gain were offset by similar amounts recorded as an increase to compensation expense within SG&A expenses.
Income Tax Provision
Our effective income tax rate was approximately 30% for the three months ended September 27, 2026 and 27% for the same period a year ago. The effective income tax rate for each period exceeded the U.S. federal statutory rate of 21%, primarily due to state income taxes on non-deductible expenses, including executive compensation and other permanent items. The increase in the effective income tax rate compared with prior-periods was primarily due to higher state income taxes and an increase in non-deductible items. The effective tax rate is impacted by projected levels of annual taxable income, permanent items, state taxes and discrete items, including tax effects of stock-based compensation. Our effective tax rate for the full year is expected to be approximately 25% to 27%.
Six Months Ended September 27, 2026 Compared to Six Months Ended September 28, 2025
Sales
Sales were $629.5 million for the six months ended September 27, 2026, an increase of $55.8 million, or 10%, from sales of $573.7 million in the same period a year ago. All of our segments grew by 7% or more as compared to the prior year.
Water Treatment Segment. Water Treatment segment sales increased $32.8 million, or 11%, to $333.3 million for the six months ended September 27, 2026, from sales of $300.5 million in the same period a year ago. Sales of bulk commodity products in the Water Treatment segment were approximately 11% of sales dollars in the current period and 8% in the same period a year ago. Sales increased as a result of improved pricing and increased sales volumes on certain of our products and approximately $10.6 million of added sales from acquired businesses.
Food & Health Sciences Segment. Food & Health Sciences segment sales increased $11.8 million or 7%, to $173.9 million for the six months ended September 27, 2026, from sales of $162.1 million in the same period a year ago. Sales dollars increased as a result of increased volumes of our agricultural, nutrition, and pharmaceutical products, partially offset by decreased sales volumes of our food ingredients products.
Industrial Solutions Segment. Industrial Solutions segment sales increased $11.2 million, or 10%, to $122.3 million for the six months ended September 27, 2026, from sales of $111.1 million in the same period a year ago. Sales of bulk commodity products in the Industrial Solutions segment were approximately 21% of sales dollars in both the current period and the same period a year ago. Sales increased primarily as a result of improved pricing of certain of our manufactured, blended and repackaged products.
Gross Profit
Gross profit increased $10.6 million, or 8%, to $150.6 million, or 24% of sales, for the six months ended September 27, 2026, from $140.0 million, or 24% of sales, in the same period a year ago. During the current period, the LIFO reserve increased, and gross profit decreased, by $3.9 million due primarily to a projected increase in certain commodity volumes and costs at year end. In the same period a year ago, the LIFO reserve increased, and gross profit decreased, by $0.9 million. The $3.0 million year-over-year increase in the unfavorable LIFO impact on gross profit was partially offset by $1.3 million of refunds of previously paid tariffs, which were recorded as a reduction of cost of sales. The refunded tariffs related to products for which customer pricing had not been increased in response to tariffs.
Water Treatment Segment. Gross profit for the Water Treatment segment increased $10.2 million, or 12%, to $97.2 million, or 29% of sales, for the six months ended September 27, 2026, from $87.0 million, or 29% of sales, in the same period a year ago. During the current year, the LIFO reserve increased, and gross profit decreased, by $1.1 million. During the prior year the LIFO reserve increased, and gross profit decreased, by $0.2 million. The $0.9 million year-over-year impact of the unfavorable LIFO reserve was more than offset by $1.2 million of refunds of previously paid tariffs, which were recorded as a reduction of cost of sales. Gross profit increased primarily as a result of organic and inorganic sales growth.
Food & Health Sciences Segment. Gross profit for the Food & Health Sciences segment decreased $0.6 million, or 2%, to $34.2 million, or 20% of sales, for the six months ended September 27, 2026, from $34.8 million, or 21% of sales, in the same period a year ago. During the current year, the LIFO reserve increased, and gross profit decreased, by $1.5 million. During the prior year the LIFO reserve increased, and gross profit decreased, by $0.4 million. Gross profit decreased primarily as a result of the $1.1 million year-over-year impact of the unfavorable LIFO reserve increase, partially offset by the increase in sales.
Industrial Solutions Segment. Gross profit for our Industrial Solutions segment increased $1.0 million, or 6%, to $19.2 million, or 16% of sales, for the six months ended September 27, 2026, from $18.2 million, or 16% of sales, in the same period a year ago. During the current year, the LIFO reserve increased, and gross profit decreased, by $1.3 million. During the prior year the LIFO reserve increased, and gross profit decreased, by $0.3 million. Gross profit increased due to higher sales, partially offset by the $1.0 million year-over-year impact of the unfavorable LIFO reserve increase.
Selling, General and Administrative Expenses
SG&A expenses increased $5.3 million, or 8%, to $70.0 million, or 11% of sales, for the six months ended September 27, 2026, from $64.7 million, or 11% of sales, in the same period a year ago. This included $2.2 million in added costs from the acquired businesses in our Water Treatment segment. In addition, the prior-year period included a $1.9 million favorable fair value adjustment that reduced SG&A, reflecting a downward revision to the estimated Water Solutions earnout liability based on a change in projected estimates related to the earnout target. This benefit did not recur in the current period, resulting in a $1.9 million year-over-year increase in SG&A. SG&A expenses also increased due to increases in other variable costs, including variable pay and personnel costs.
Operating Income
Operating income increased $5.3 million, or 7%, to $80.6 million, or 13% of sales, for the six months ended September 27, 2026, from $75.3 million, or 13% of sales, in the same period a year ago due to the combined impact of the factors discussed above.
Interest Expense, Net
Interest expense decreased $1.7 million to $5.4 million for the six months ended September 27, 2026, from $7.1 million in the same period a year ago. Interest expense decreased due to a decrease in outstanding borrowings in the current year as compared to a year ago as well as slightly lower interest rates.
Other Income
Other income was $1.7 million for both the six months ended September 27, 2026 and the same period a year ago. The income represents gains recorded on investments held for our non-qualified deferred compensation plan. The amounts recorded as a gain were offset by similar amounts recorded as an increase to compensation expense within SG&A expenses.
Income Tax Provision
Our effective income tax rate was 27% for the six months ended September 27, 2026 and 26% for the same period a year ago. The effective tax rate is impacted by projected levels of annual taxable income, permanent items, state taxes and discrete items, including tax effects of stock-based compensation. Our effective tax rate for the full year is currently expected to be approximately 25% to 27%.
Liquidity and Capital Resources
Cash was $7.1 million at September 27, 2026, an increase of $3.2 million as compared with the $3.9 million available as of March 29, 2026.
Cash provided by operating activities was $75.5 million for the six months ended September 27, 2026, compared to cash provided by operating activities of $71.0 million in the same period a year ago. The year-over-year increase in cash provided by operating activities in the current period was primarily driven by favorable year-over-year changes in net income and accounts payable compared to the same period a year ago, which was offset by unfavorable changes in accounts receivable and inventories. Due to the nature of our operations, which includes purchases of large quantities of bulk chemicals, the timing of purchases can result in significant changes in working capital investment and the resulting operating cash flow.
Cash used in investing activities was $27.0 million for the six months ended September 27, 2026, compared to $185.8 million in the same period a year ago. In the current period, we incurred acquisition spending of $5.2 million compared to $162.5 million in the same period a year ago, including the acquisition of WaterSurplus for approximately $149.9 million paid at closing. Capital expenditures were $22.4 million for the current period, compared to $24.3 million in the same period a year ago. In the current period, we expended less on delivery vehicles and trailers, contributing to the overall decrease in capital expenditures compared to the prior year.
Cash used in financing activities was $45.3 million for the six months ended September 27, 2026, compared to $120.1 million of cash provided by financing activities in the same period a year ago. Included in financing activities in the current period were $15.0 million net debt payments, compared to net debt borrowings of $130.0 million in the same period a year ago when we drew approximately $150 million of proceeds from the Revolving Loan Facility for the acquisition of WaterSurplus. In addition, we repurchased $18.6 million of our common stock in the current period, compared to no repurchases in the same period of the prior year.
We expect our cash balances and funds available under our credit facility, discussed below, along with cash flows generated from operations, will be sufficient to fund the cash requirements of our ongoing operations for the foreseeable future.
Our Board has authorized the repurchase of up to 2.6 million shares of our outstanding common shares. The shares may be purchased on the open market or in privately negotiated transactions subject to applicable securities laws and regulations. The primary objective of the share repurchase program is to offset the impact of dilution from issuances relating to employee and director equity grants and our employee stock purchase program. During the six months ended September 27, 2026, we repurchased 132,577 shares of common stock at an aggregate purchase price of $18.6 million. During the six months ended September 28, 2025, we repurchased no shares of common stock. As of September 27, 2026, 598,967 shares remained available to be repurchased under the share repurchase program.
We are party to a second amended and restated credit agreement with U.S. Bank National Association ("U.S. Bank") as administrative agent, sole lead arranger and sole book runner, and the other lenders from time to time party thereto (collectively, the "Lenders"), dated as of March 31, 2022 (as amended, restated or modified from time to time, the "Credit Agreement"). A Joinder, Consent and Second Amendment, dated April 25, 2025 increased the revolving commitment under the Credit Agreement to provide us with senior secured revolving credit facilities (the "Revolving Loan Facility") totaling $400.0 million. A Third Amendment, dated October 15, 2025, modified terms related to qualified receivables transactions, as defined in the Credit Agreement. The Revolving Loan Facility includes a $10.0 million letter of credit subfacility and $25.0 million swingline subfacility. The Revolving Loan Facility has a five-year maturity date, maturing on April 25, 2030. The Revolving Loan Facility is secured by substantially all of our personal property assets and those of our subsidiaries. We may use the amount available under the Revolving Loan Facility for working capital, capital expenditures, share repurchases, restricted payments and acquisitions permitted under the Credit Agreement, and other general corporate purposes. At September 27, 2026, we had $229.0 million outstanding under the Revolving Loan Facility.
Borrowings under the Revolving Loan Facility bear interest at a rate per annum equal to one of the following, plus, in both cases, an applicable margin based upon our leverage ratio: (a) Term SOFR, for an interest period of one, three or six months as selected by us, reset at the end of the selected interest period, or (b) a base rate determined by reference to the highest of (1) U. S. Bank's prime rate, (2) the Federal Funds Effective Rate plus 0.5%, or (3) one-month Term SOFR for U.S. dollars plus 1.0%.
The Term SOFR margin is between 1.0% and 1.85%, depending on our leverage ratio. The base rate margin is between 0.00% and 0.85%, depending on our leverage ratio. At September 27, 2026, the effective interest rate on our borrowings was 4.3%.
In addition to paying interest on the outstanding principal under the Revolving Loan Facility, we are required to pay a commitment fee on the unutilized commitments thereunder. The commitment fee is between 0.15% and 0.25%, depending on our leverage ratio.
Debt issuance costs paid to the Lenders are being amortized as interest expense over the term of the Credit Agreement. As of September 27, 2026, the unamortized balance of these costs was $0.7 million, and is included within other long-term assets on our condensed consolidated balance sheet.
The Credit Agreement requires that we maintain (a) a minimum fixed charge coverage ratio of 1.15 to 1.00 and (b) a maximum total cash flow leverage ratio of 3.5 to 1.0, subject to an election by us to increase the maximum total cash flow leverage ratio to 4.0 to 1.0 after certain Permitted Acquisitions subject to limitations set forth in the Credit Agreement. The Credit Agreement also contains other customary affirmative and negative covenants, including covenants that restrict our ability to incur additional indebtedness, dispose of significant assets, make certain investments, including any acquisitions other than permitted acquisitions, make certain payments, enter into sale and leaseback transactions, grant liens on its assets or rate management transactions, subject to certain limitations.
We are permitted to make distributions, pay dividends and repurchase shares so long as no default or event of default exists or would exist as a result thereof. We were in compliance with all covenants of the Credit Agreement as of September 27, 2026 and expect to remain in compliance with all covenants for the next 12 months.
The Credit Agreement contains customary events of default including failure to make payments under the Revolving Loan Facility, failure to comply with covenants in the Credit Agreement and other loan documents, cross default to other material indebtedness, our failure to pay or discharge material judgments, bankruptcy, and change of control of the Company. The occurrence of an event of default would permit the lenders to terminate their commitments and accelerate loans under the Revolving Loan Facility.
We have in place an interest rate swap agreement to manage the risk associated with a portion of our variable-rate long-term debt. We do not utilize derivative instruments for speculative purposes. The interest rate swap involves the exchange of fixed-rate and variable-rate payments without the exchange of the underlying notional amount on which the interest payments are calculated. The notional amount of the swap agreement is $60 million, and it will terminate on May 1, 2027.
As part of our growth strategy, we have acquired businesses and may pursue acquisitions or other strategic relationships in the future that we believe will complement or expand our existing businesses or increase our customer base. We believe we could borrow additional funds under our current or new credit facilities or sell equity for strategic reasons or to further strengthen our financial position. We believe that our existing cash and cash equivalents, together with cash generated from operations and available borrowings under our existing Credit Agreement, will be sufficient to meet our working capital expenditure requirements for at least the next 12 months.
Critical Accounting Estimates
There have been no material changes in our critical accounting estimates, as disclosed in our Annual Report on Form 10-K for fiscal 2026.
Forward-Looking Statements
The information presented in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements have been made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts, but rather are based on our current expectations, estimates and projections, and our beliefs and assumptions. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and similar expressions may identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. These factors could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Additional information concerning potential factors that could affect future financial results is included in our Annual Report on Form 10-K for fiscal 2026. We caution you not to place undue reliance on these forward-looking statements, which reflect our management's view only as of the date of this Quarterly Report on Form 10-Q. We are not obligated to update these statements or publicly release the result of any revisions to them to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.
Hawkins Inc. published this content on October 26, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on October 26, 2026 at 20:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]